Evidence current through August 2026

BPC-157

Synthetic linear pentadecapeptide GEPPPGKPADDAGLV

BPC-157 is a chemically synthesized linear peptide composed of 15 amino acids: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, commonly abbreviated as GEPPPGKPADDAGLV.

The name is often expanded as “Body Protection Compound 157,” and the peptide is frequently described as a “stable gastric pentadecapeptide.” Those phrases reflect its development history, but they require context. The Zagreb research group that originated the program described a larger bioactive material isolated from human gastric juice and proposed that the synthetic 15-residue sequence retained part of its activity.

Research areas

Molecular identity
Endogenous-human origin
Gastric injury
Tendon and ligament models
Independent repaired-Achilles study
Cell migration and angiogenesis
Muscle, bone, nerve, fistula, and organ recovery
Human controlled trials
Human observational reports
Human pharmacokinetics
Safety

Evidence at a glance

What the current record supports

Molecular identity: A defined synthetic 15-residue peptide; free base, acetate, and other salts are distinct material descriptions

Endogenous-human origin: Historical gastric-juice narrative without modern sequence-confirmed identification of the exact free 15-mer

Gastric injury: Multiple animal programs, including some independent work, reported reduced experimentally induced gastric lesions

Tendon and ligament models: Originating-network studies reported functional, mechanical, histologic, and collagen-related findings

Qualification

Limitations and evidence gaps

Limitations and contradictory findings

Most BPC-157 publications come from one interconnected investigator network, and related models or cohorts should not be counted as independent replication. The evidence is predominantly preclinical, often with small animal samples and limited reporting of masking, power, or multiplicity. Outside-network replication is narrow, and some musculoskeletal findings are mixed or null.

No completed randomized human study has been published in full. Animal histology, biomarkers, lesion area, and cell-migration findings do not establish human healing or clinical benefit, and differences in free base, acetate, impurities, aggregation, sterility, and endotoxin limit comparisons across test materials.

Safety and evidence gaps

Published studies do not adequately address chronic toxicity, carcinogenicity, fertility, pre- or postnatal development, juvenile exposure, immunogenicity, aggregation, or delayed human adverse effects. FDA review also identified incomplete toxicology reporting and changes in coagulation, liver enzymes, glucose, triglycerides, hematology, and creatinine that require qualification rather than blanket safety claims.

Human pharmacokinetics, target pharmacology, and long-term safety remain unresolved. Route-specific impurities, sterility, endotoxin, residual solvents, and uncertain product form create safety questions separate from the pharmacology of a correctly identified peptide.

Research path

Connected research articles

Overview

BPC-157 Research Overview

BPC-157 is a chemically synthesized linear peptide composed of 15 amino acids: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, commonly abbreviated as GEPPPGKPADDAGLV.

Read overview

Full review

BPC-157 Full Evidence Review

BPC-157 is a chemically synthesized linear 15-amino-acid peptide, GEPPPGKPADDAGLV, commonly described as a stable gastric pentadecapeptide. Its synthetic identity is established; its frequently claimed status as an endogenous human peptide is not. No independently...

Read evidence review

Study map

Connected study records

Compound referenceSee approved evidence mapCompleted

Frontiers in Pharmacology

BPC-STUDY-P007

He L, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157 in rats and dogs. Frontiers in Pharmacology. 2022;13:1026182. DOI: 10.3389/fphar.2022.1026182. PMID: 36588717.